Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Receivables - Accured (2019 - 2025)

Historic Receivables - Accured for Fate Therapeutics (FATE) over the last 7 years, with Q3 2025 value amounting to $1.4 million.

  • Fate Therapeutics' Receivables - Accured fell 2631.58% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 2631.58%. This contributed to the annual value of $2.1 million for FY2024, which is 13333.33% up from last year.
  • As of Q3 2025, Fate Therapeutics' Receivables - Accured stood at $1.4 million, which was down 2631.58% from $2.0 million recorded in Q2 2025.
  • Fate Therapeutics' Receivables - Accured's 5-year high stood at $2.1 million during Q2 2021, with a 5-year trough of $1000.0 in Q2 2022.
  • Over the past 5 years, Fate Therapeutics' median Receivables - Accured value was $1.4 million (recorded in 2022), while the average stood at $1.3 million.
  • In the last 5 years, Fate Therapeutics' Receivables - Accured tumbled by 9995.24% in 2022 and then surged by 15444545.45% in 2024.
  • Fate Therapeutics' Receivables - Accured (Quarter) stood at $1.1 million in 2021, then decreased by 27.27% to $800000.0 in 2022, then rose by 12.5% to $900000.0 in 2023, then surged by 133.33% to $2.1 million in 2024, then crashed by 33.33% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $2.0 million for Q2 2025, and $2.0 million during Q1 2025.